Merck Sharp + Dohme Corp.

Jared K Lunceford

Terrill K McClanahan

Mark David Ayers

Michael V Nebozhyn

Andrey Loboda

Erin E Murphy

Heather Hirsch

Terrill K Mcclanahan

A gene expression platform, which is a combination of a set of genes that are correlated with response to a PD-1 antagonist in multiple tumor types and a normalization gene set, is disclosed. A method and system of using the gene expression platform to derive gene signature biomarkers of anti-tumor response to a PD-1 antagonist and to test patient samples for predictive gene signature biomarkers are also disclosed.

System and methods for deriving gene signature biomarkers of response to PD-1 antagonists

The present disclosure describes baseline and on treatment blood-based gene signature biomarkers that are predictive of tumor sensitivity to therapy with a PD-1 antagonist. The on-treatment biomarkers comprise a PD-L1 gene signature or an interferon gamma gene signature and the baseline gene signature biomarker comprises genes associated with the oxidative phosphorylation pathway. The disclosure also provides methods and kits for testing tumor samples for these biomarkers, as well as methods for treating subjects with a PD-1 antagonist based on the test results.

Blood-based biomarkers of tumor sensitivity to PD-1 antagonists

Growing community of inventors

Washington, UT, United States of America

Jared K Lunceford